MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce changes to its Board of Directors.
MedX welcomes two new members to its Board of Directors; Mr. Stephen Lockyer and Mr. Ed Ho, who both bring many years and wide-ranging business and entrepreneurial experience. Mr. Lockyer is the President and Owner of Armshore Investments Limited, based in Nova Scotia, a venture capital investor in real estate and early-stage technology companies. Mr. Ho, who is a Chartered Financial Analyst, has years of experience as a Portfolio Manager with a major mutual fund, covering diverse mandates, including venture capital, tax strategies, and management of both small-cap and large-cap investment funds.
Additionally, the Board is pleased to announce that Mr. David Hennigar, a Director of MedX since 2001, has been appointed to Vice-Chairman. MedX also announces the retirement of Mr. Wayne Cockburn as a Director and wishes him the best in his future endeavours.
“The Board looks forward to the invaluable expertise and counsel that both Mr. Lockyer and Mr. Ho will bring to the Company, especially at a point where MedX’s SIAscopy® technology and DermSecure® platform are being launched widely across Canada. We also wish to thank Mr. Cockburn for his service since he joined the Board in October 2020,” said Ken McKay, Chairman of the MedX Board.
About MedX Health Corp.
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Bill Mitoulas, Investor Relations
MedX Health Corp.